Literature DB >> 22005528

Summary of presentation from the targeted therapy in lung cancer meeting.

Ramaswamy Govindan1.   

Abstract

New pathways are being identified now on a regular basis, and novel agents are being tested in a wide variety of clinical trials for patients with advanced non-small cell lung cancer. Excitement over progress in one area is tempered naturally by disappointing results in other areas. Each year, leading lung cancer experts meet in Santa Monica to discuss the progress in the field of molecularly targeted therapy in non-small cell lung cancer. Annual conferences similar to the one held in Santa Monica serve mainly as a catalyst to promote new ideas and foster active collaboration. We have invited participants to provide very brief succinct summaries of the presentations for this supplement. The articles in this supplement should be viewed more as meeting reports than as exhaustive and comprehensive review articles.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22005528     DOI: 10.1097/JTO.0b013e31822eec73

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  2 in total

1.  Expression of fibroblast growth factor receptor 1, fibroblast growth factor 2, phosphatidyl inositol 3 phosphate kinase and their clinical and prognostic significance in early and advanced stage of squamous cell carcinoma of the lung.

Authors:  Cigdem Usul Afsar; Berksoy Sahin; Meral Gunaldi; Emine Kılıc Bagir; Derya Gumurdulu; Refik Burgut; Melek Erkisi; Ismail Oguz Kara; Semra Paydas; Feryal Karaca; Vehbi Ercolak
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

2.  Year-in-Review of Lung Cancer.

Authors:  Ji Woong Son
Journal:  Tuberc Respir Dis (Seoul)       Date:  2012-09-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.